X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (37) 37
aged (25) 25
female (25) 25
index medicus (25) 25
male (25) 25
middle aged (23) 23
oncology (22) 22
adult (21) 21
aged, 80 and over (19) 19
lung neoplasms - drug therapy (19) 19
respiratory system (16) 16
chemotherapy (15) 15
gefitinib (15) 15
carcinoma, non-small-cell lung - drug therapy (14) 14
lung neoplasms - pathology (14) 14
lung cancer (11) 11
cancer (10) 10
treatment outcome (10) 10
tyrosine kinase inhibitor (10) 10
lung neoplasms - genetics (9) 9
non-small cell lung cancer (9) 9
epidermal growth factor receptor (8) 8
erlotinib (8) 8
lung neoplasms - mortality (8) 8
quinazolines - therapeutic use (8) 8
receptor, epidermal growth factor - genetics (8) 8
adenocarcinoma - drug therapy (7) 7
carcinoma, non-small-cell lung - pathology (7) 7
care and treatment (7) 7
lung cancer, non-small cell (7) 7
neoplasm staging (7) 7
prognosis (7) 7
retrospective studies (7) 7
survival analysis (7) 7
tumors (7) 7
adenocarcinoma - genetics (6) 6
antineoplastic agents - pharmacology (6) 6
antineoplastic agents - therapeutic use (6) 6
disease-free survival (6) 6
medicine (6) 6
metastasis (6) 6
mutation (6) 6
non-small-cell lung cancer (6) 6
1st-line treatment (5) 5
adenocarcinoma - pathology (5) 5
carcinoma, non-small-cell lung - mortality (5) 5
cisplatin (5) 5
cmos technology (5) 5
egfr (5) 5
growth-factor receptor (5) 5
medicine, general & internal (5) 5
open-label (5) 5
respiratory tract diseases (5) 5
survival (5) 5
survival rate (5) 5
transceivers (5) 5
adenocarcinoma (4) 4
cancer patients (4) 4
carboplatin (4) 4
carcinoma, non-small-cell lung - genetics (4) 4
carcinoma, squamous cell - drug therapy (4) 4
cell line, tumor (4) 4
cohort studies (4) 4
egfr mutations (4) 4
epidermal growth factor (4) 4
follow-up studies (4) 4
internal medicine (4) 4
lung adenocarcinoma (4) 4
lung neoplasms - therapy (4) 4
multicenter (4) 4
mutations (4) 4
noise figure (4) 4
phase-iii trial (4) 4
resistance (4) 4
smoking (4) 4
therapy (4) 4
trial (4) 4
tyrosine (4) 4
tyrosine kinase (4) 4
tyrosine kinase inhibitors (4) 4
zd1839 (4) 4
abridged index medicus (3) 3
adenocarcinoma - mortality (3) 3
adenocarcinoma of lung (3) 3
antineoplastic agents - adverse effects (3) 3
bacterial pneumonia (3) 3
cancer cells (3) 3
cancer research (3) 3
carcinoma, non-small-cell lung - metabolism (3) 3
cavitation (3) 3
cell biology (3) 3
cell lung-cancer (3) 3
combination (3) 3
down-regulation (3) 3
drug administration schedule (3) 3
egfr mutation (3) 3
erbb receptors - antagonists & inhibitors (3) 3
expression (3) 3
hematology, oncology and palliative medicine (3) 3
interleukin-6 (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lung Cancer, ISSN 0169-5002, 12/2019, Volume 138, pp. 52 - 57
Brain metastasis (BM) is common in patients with epidermal growth factor receptor (EGFR)-mutant lung cancer. However, the brain surveillance strategy during... 
Epidermal growth factor receptor mutation | Surveillance | Brain metastasis | Non-small cell lung cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e21145 - e21145
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 8548 - 8548
Journal Article
Spinal cord, ISSN 1362-4393, 09/2019
Retrospective cohort study. To compare the surgical results between targeted therapy and post-operative chemotherapy for patients with spinal metastasis of... 
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2019, Volume 30, Issue Supplement_6
Abstract Background Dual blockade of the EGFR and VEGFR pathways in EGFR mutation-positive NSCLC is more effective than EGFR inhibition alone. EGFR mutations... 
Journal Article
by Mok, Tony and Mok, Tony S K and Wu, Yilong and Wu, Yi-Long and Kudaba, Iveta and Kowalski, Dariusz M and Kowalski, Dariusz and Cho, Byoung Chul and Turna, Hande and Turna, Hande Z and Castro, Hugo and Castro, Gilberto and Srimuninnimit, Vichien and Laktionov, Konstantin and Laktionov, Konstantin K and Bondarenko, Igor and Kubota, Kaoru and Lubiniecki, Gregory M and Zhang, Jin and Zhang, Li and Zhang, Xin and Kush, Debra and Lopes, Valeria and Lopes, Gilberto and Adamchuk, Grigory and Ahn, Myung-Ju and Alexandru, Aurelia and Altundag, Ozden and Alyasova, Anna and Andrusenko, Orest and Aoe, Keisuke and Araujo, Antonio and Aren, Osvaldo and Arrieta Rodriguez, Oscar and Ativitavas, Touch and Avendano, Oscar and Barata, Fernando and Barrios, Carlos Henrique and Beato, Carlos and Bergstrom, Per and Betticher, Daniel and Bolotina, Larisa and Botha, Michiel and Buddu, Sayeuri and Caglevic, Christian and Cardona, Andres and Cay Senler, Filiz and Cerny, Carlos Alexandre Sydow and Cesas, Alvydas and Chan, Gee-Chen and Chang, Jianhua and Chen, Xi and Chen, Gongyan and Cheng, Ying and Cheng, Susanna and Cherciu, Nelly and Chiu, Chao-Hua and Cicenas, Saulius and Ciurescu, Daniel and Cohen, Graham and Costa, Marcos Andre and Danchaivijitr, Pongwut and De Angelis, Flavia and de Azevedo, Sergio Jobim and Dediu, Mircea and Deliverski, Tsvetan and De Marchi, Pedro Rafael Martins and de The Bustamante Valles, Flor and Ding, Zhenyu and Doganov, Boyan and Dreosti, Lydia and Duarte, Ricardo and Edusma-Dy, Regina and Emelyanov, Sergey and Erman, Mustafa and Fan, Yun and Fein, Luis and Feng, Jifeng and Fenton, David and Fernandes, Gustavo and Ferreira, Carlos and Franke, Fabio Andre and Freitas, Helano and Fujisaka, Yasuhito and Galindo, Hector and Galvez, Christina and Ganea, Doina and Gil, Nuno and Girotto, Gustavo and Goker, Erdem and Goksel, Tuncay and Gomez Aubin, Gonzalo and Gomez Wolff, Luis and Griph, Hakan and Gumus, Mahmut and Hall, Jacqueline and Hart, Gregory and Havel, Libor and He, Yong and He, Jianxing and ... and KEYNOTE-042 Investigators
The Lancet, ISSN 0140-6736, 05/2019, Volume 393, Issue 10183, pp. 1819 - 1830
First-line pembrolizumab monotherapy improves overall and progression-free survival in patients with untreated metastatic non-small-cell lung cancer with a... 
MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | BEVACIZUMAB | CRIZOTINIB | NIVOLUMAB | PACLITAXEL | Genes, erbB-1 - drug effects | Lung Neoplasms - drug therapy | Translocation, Genetic | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Lung Neoplasms - metabolism | Middle Aged | Far East - epidemiology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Anaplastic Lymphoma Kinase - genetics | Antibodies, Monoclonal, Humanized - administration & dosage | Carcinoma, Non-Small-Cell Lung - secondary | Lung Neoplasms - secondary | Female | Carcinoma, Non-Small-Cell Lung - pathology | Anaplastic Lymphoma Kinase - drug effects | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Genes, erbB-1 - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Disease-Free Survival | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasm Metastasis - pathology | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Chemotherapy | Metastasis | Lung cancer, Non-small cell | Cancer | Slopes | Lung cancer | Oncology | Kinases | Cancer therapies | Metastases | Pembrolizumab | Randomization | Motivation | Platinum | Risk assessment | Population | Translocation | Cell survival | Life expectancy | Epidermal growth factor receptors | Hyperthyroidism | Histology | Hypothyroidism | Survival | Patients | Medical centres | Life span | Interactive systems | PD-L1 protein | Men | Ligands | Tumors | Apoptosis
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2014, Volume 74, Issue 4, pp. 661 - 665
Journal Article
Surgical Case Reports, ISSN 2198-7793, 12/2019, Volume 5, Issue 1, pp. 1 - 5
Some oligometastatic lung cancer patients, after induction systemic chemotherapy or tyrosine kinases inhibitor treatment, followed by aggressive radical... 
Medicine & Public Health | Oligometastases | Surgery | Pathologic complete response | Immune checkpoint inhibitors | Stereotactic radiotherapy | Tyrosine kinase inhibitors | Tomography | Vertebra | Metastasis | Biopsy | Lung cancer
Journal Article
by Nakagawa, Kazuhiko and Garon, Edward B and Garon, Edward and Seto, Takashi and Nishio, Makoto and Ponce Aix, Santiago and Paz-Ares, Luis and Chiu, Chao-Hua and Park, Keunchil and Novello, Silvia and Nadal, Ernest and Imamura, Fumio and Yoh, Kiyotaka and Shih, Jin-Yuan and Au, Kwok-Hung and Au, Kwok Hung and Moro-Sibilot, Denis and Enatsu, Sotaro and Zimmermann, Annamaria and Frimodt-Moller, Bente and Visseren-Grul, Carla and Reck, Martin and Chu, Quincy and Cortot, Alexis and Pujol, Jean-Louis and Fabre, Elizabeth and Lamour, Corinne and Bischoff, Helge and Kollmeier, Jens and Kimmich, Martin and Engel-Riedel, Walburga and Hammerschmidt, Stefan and Schütte, Wolfgang and Syrigos, Konstantinos and Ho, James Chung Man and Ardizzoni, Andrea and Pasello, Giulia and Gregorc, Vanessa and Del Conte, Alessandro and Galetta, Domenico and Takahashi, Toshiaki and Kumagai, Toru and Hotta, Katsuyuki and Goto, Yasushi and Hosomi, Yukio and Sakai, Hiroshi and Takiguchi, Yuichi and Kim, Young Hak and Kim, Sang-We and Kim, Jin-Soo and Kurata, Takayasu and Yamaguchi, Hiroyuki and Daga, Haruko and Okamoto, Isamu and Satouchi, Miyako and Ikeda, Satoshi and Kasahara, Kazuo and Atagi, Shinji and Azuma, Koichi and Aoe, Keisuke and Horio, Yoshitsugu and Yamamoto, Nobuyuki and Tanaka, Hiroshi and Watanabe, Satoshi and Nogami, Naoyuki and Ozaki, Tomohiro and Koyama, Ryo and Hirashima, Tomonori and Kaneda, Hiroyasu and Tomii, Keisuke and Fujita, Yuka and Seike, Masahiro and Nishimura, Naoki and Kato, Terufumi and Ichiki, Masao and Saka, Hideo and Hirano, Katsuya and Nakahara, Yasuharu and Sugawara, Shunichi and Min, Young Joo and Lee, Gyeong-Won and Lee, Ki Hyeong and Lee, Sung Yong and Lee, Hyun Woo and Kang, Jin-Hyoung and An, Ho Jung and Alexandru, Aurelia and Udrea, Anghel Adrian and Juan-Vidal, Óscar and Nadal-Alforja, Ernest and Gil-Bazo, Ignacio and Ponce-Aix, Santiago and Rubio-Viqueira, Belén and Alonso Garcia, Miriam and Felip Font, Enriqueta and Fuentes Pradera, Jose and Coves Sarto, Juan and Lin, Meng-Chih and Su, Jian and Su, Wu-Chou and ...
The Lancet Oncology, ISSN 1470-2045, 12/2019, Volume 20, Issue 12, pp. 1655 - 1669
Dual blockade of the EGFR and VEGF pathways in -mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the... 
Journal Article